The North Texas Hepatitis B Consortium (NTHBC) comprises two medical institutions, and three distinct practice locations in the Dallas Fort Worth metroplex. NTHBC has participated fully in the first 7-year grant cycle, with the third highest enrollment among the 13 participating sites, good retention and ongoing participation in the Immune Active and Immune Tolerant clinical therapy trials. Drs. Perrillo and Lee have served on a variety of committees and proposed a number of ancillary studies, some of which are already under way. One of the goals of HBRN is to better define the varied immunologic presentations of chronic infection. Along these lines, the NTHBC proposes an ancillary study of a currently poorly explored sub-phenotype, that of concurrent hepatitis B surface antigen and anti-HBs. Herein, we review what is currently known about this anomalous group of patients, and seek to compare this group with others such as patients in a parallel network, the Acute Liver Failure Study Group, that is overseen by Dr. Lee. Prior studies in hepatitis B related acute liver failure (HBVALF) suggest that more than 50% of ALF patients are concurrently HBsAg and anti-HBs positive. Data from HBRN suggest that at least 6% of chronic hepatitis B subjects display this dual serologic status but appear to lack very active liver disease. One explanation might be that concurrent positivity results from infection with different subtypes but this is not substantiated y data suggesting common epitopes across all HBsAg genotypes and serotypes. The current study aims to explore the phenotype further, correlating it with clinical disease features, length of infection and time to subsequent HBsAg clearance and disease evolution over time. Understanding this phenotype better will lay the groundwork for molecular sequencing studies to better understand the mutation profile of the concurrently positive patients as compared to those with HBV ALF (typically more frequent mutations) and those with chronic hepatitis B without concurrence. These analyses are likely to offer new and important insights into HBV-specific immunological paralysis that leads to chronic infection, yielding new strategies for viral clearance.

Public Health Relevance

Hepatitis B virus infection affects more than 350 million people worldwide and more than 2 million Americans and is a common cause of liver cancer and cirrhosis. While current therapies may suppress viral replication, they have little impact in eradicating the virus. New insights provided by the Hepatitis B Research Network are directed at clarifying why there is an immune paralysis apparent in these patients and how to overcome it.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01DK082872-09
Application #
9133352
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Doo, Edward
Project Start
2008-09-30
Project End
2020-05-31
Budget Start
2016-06-01
Budget End
2017-05-31
Support Year
9
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Khalili, Mandana; Shuhart, Margaret C; Lombardero, Manuel et al. (2018) Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B. Diabetes Care 41:1251-1259
Di Bisceglie, A M; Lombardero, M; Teckman, J et al. (2017) Determination of hepatitis B phenotype using biochemical and serological markers. J Viral Hepat 24:320-329
Lok, A S; Ganova-Raeva, L; Cloonan, Y et al. (2017) Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment. J Viral Hepat 24:1032-1042
Reddy, K Rajender; Ellerbe, Caitlyn; Schilsky, Michael et al. (2016) Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States. Liver Transpl 22:505-15
Evon, Donna M; Wahed, Abdus S; Johnson, Geoffrey et al. (2016) Fatigue in Patients with Chronic Hepatitis B Living in North America: Results from the Hepatitis B Research Network (HBRN). Dig Dis Sci 61:1186-96
Park, Jang-June; Wong, David K; Wahed, Abdus S et al. (2016) Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Gastroenterology 150:684-695.e5
Khalili, Mandana; Lombardero, Manuel; Chung, Raymond T et al. (2015) Diabetes and prediabetes in patients with hepatitis B residing in North America. Hepatology 62:1364-74
Dao, Doan Y; Seremba, Emmanuel; Ajmera, Veeral et al. (2012) Use of nucleoside (tide) analogues in patients with hepatitis B-related acute liver failure. Dig Dis Sci 57:1349-57
Dao, Doan Y; Hynan, Linda S; Yuan, He-Jun et al. (2012) Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum immunoglobulin M anti-hepatitis B core antibody and hepatitis B virus DNA levels. Hepatology 55:676-84
Chung, Raymond T; Stravitz, R Todd; Fontana, Robert J et al. (2012) Pathogenesis of liver injury in acute liver failure. Gastroenterology 143:e1-e7

Showing the most recent 10 out of 11 publications